Nuvation Bio Inc. (NUVB) is a publicly traded Healthcare sector company. As of July 7, 2026, NUVB trades at $5.56 with a market cap of $1.98B and a P/E ratio of -13.46. NUVB moved -3.16% today. Year to date, NUVB is -37.36%; over the trailing twelve months it is +167.94%. Its 52-week range spans $1.54 to $9.75. Analyst consensus is strong buy with an average price target of $14.40. Rallies surfaces NUVB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Nuvation Bio Raises $287.5M via 0.75% Convertible Notes, Executes $37.5M Greenshoe: Nuvation Bio has raised $287.5 million in a 0.75% convertible senior notes due 2032 by fully exercising a $37.5 million greenshoe option. Additional capped call transactions at a $10.458 cap price cost approximately $2.2 million, leaving about $277.6 million in net proceeds for general corporate purposes and working capital.
| Metric | Value |
|---|---|
| Price | $5.56 |
| Market Cap | $1.98B |
| P/E Ratio | -13.46 |
| EPS | $-0.42 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.75 |
| 52-Week Low | $1.54 |
| Volume | 4.78M |
| Avg Volume | 0 |
| Revenue (TTM) | $143.05M |
| Net Income | $-145.99M |
| Gross Margin | 0.00% |
7 analysts cover NUVB: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.40.